Vor Biopharma Inc. - Common Stock (NQ:VOR)

18.58 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage ↗

December 09, 2025

Via Stocktwits

Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch ↗

December 09, 2025

The Dow Jones futures were up by 0.11% while the S&P 500 futures were up 0.04%.

Via Stocktwits

Topics ETFs Economy Government

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

From Vor Biopharma

Via GlobeNewswire

Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗

November 11, 2025

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

November 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗

November 11, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 11, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 11, 2025

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial ↗

November 11, 2025

Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA nephropathy.

Via Benzinga

US Stocks Mixed; Sea Shares Gain After Q3 Results ↗

November 11, 2025

Via Benzinga

Get insights into the top gainers and losers of Tuesday's pre-market session. ↗

November 11, 2025

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 11, 2025

Via Benzinga

Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

November 11, 2025

Via Benzinga

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

November 10, 2025

From Vor Biopharma

Via GlobeNewswire

These stocks are moving in today's after hours session ↗

November 10, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

November 10, 2025

From Vor Biopharma

Via GlobeNewswire

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

November 08, 2025

From Vor Biopharma

Via GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

November 07, 2025

From Vor Biopharma

Via GlobeNewswire

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

November 03, 2025

From Vor Biopharma

Via GlobeNewswire

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 31, 2025

From Vor Biopharma

Via GlobeNewswire

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

October 29, 2025

From Vor Biopharma

Via GlobeNewswire

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

October 22, 2025

From Vor Biopharma

Via GlobeNewswire

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

October 17, 2025

From Vor Biopharma

Via GlobeNewswire

Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗

October 16, 2025

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Via Benzinga

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

October 16, 2025

From Vor Biopharma

Via GlobeNewswire

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗

October 14, 2025

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints.

Via Benzinga

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

October 14, 2025

From Vor Biopharma

Via GlobeNewswire

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From Vor Biopharma

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 01, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.